Independent PatientView Survey

Corporate Reputation of Pharma 2024/5: Now Published

■ Two decades of experience
■ An extensive evidence base of patient-group views
■ 46 companies involved
■ Now in its 14th year
■ Database of 40,000 patient groups worldwide
■ Survey conducted in 23 languages
■ Analyses based on geographic regions and therapy areas
■ Feedback from 2500+ patient groups in 2025; a record number

Respondent patient groups 2024/25:familiarity and partnerships with pharma

Specialities of patient-group respondents 2024/25

Country headquarters of respondent patient groups

Pharmaceutical companies included in PatientView’s Corporate Reputation of Pharma 2024/2025:

New companies for 2024/2025 included in bold*:

AbbVie • Amgen / including Horizon • Alnylam Pharmaceuticals • Angelini Pharma • Astellas Pharma • AstraZeneca / including Alexion • Bayer • Biogen • BioMarin • Boehringer Ingelheim • Bristol Myers Squibb • Chiesi / including Amyrt • Crinetics Pharmaceuticals • CSL Behring • Daiichi Sankyo • Eisai • Esteve Healthcare • Eli Lilly • Exelixis • Gilead Sciences / including Kite Pharma • GSK • Incyte • Ipsen • Johnson & Johnson Innovative Medicine (formerly Janssen) • Jazz Pharmaceuticals • LEO Pharma • Lundbeck • Merck KGaA/EMD Serono • Merck & Co/MSD • Novartis • Novo Nordisk • Otsuka • Pfizer • PTC Therapeutics • Recordati • Regeneron Pharmaceuticals • Roche/Genentech/Chugai • Sanofi • Sarepta Therapeutics • Servier • Sobi • Takeda • UCB • Vertex • Viatris • ViiV Healthcare

Click here for more on PatientView’s Corporate Reputation of Pharma report

For more information or to inquire about the Corporate Reputation of Pharma report, please contact PatientView using the form below.

    Up